

Special Issue

Recent Strategies in Anti-influenza Therapeutics

Message from the Guest Editor

As demonstrated by COVID-19, viruses are able to generate pandemics with a devastating socioeconomic impact in the world. In 1918, humanity witnessed the deadliest pandemic in human history, the Spanish flu, which caused extraordinary mortality around the globe. Nevertheless, during recent years, major breakthroughs have been made in the development of new anti-flu agents endowed with a different mode of action. Several agents have entered the clinical pipeline, many of which target the viral hemagglutinin and polymerase complex. This Special Issue, entitled “Recent Strategies in Anti-Influenza Therapeutics”, will focus on the development of new anti-flu agents, but also on studies aimed at understanding the molecular mechanisms of flu replication that are essential in order to identify new therapeutic targets.

Guest Editor

Dr. Serena Massari

Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy

Deadline for manuscript submissions

closed (28 February 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/54247

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)